**Core Concept**
Chlorpropamide is a first-generation sulfonylurea that not only stimulates insulin release but also has a unique property of enhancing the release of antidiuretic hormone (ADH) from the posterior pituitary gland, thereby treating diabetes insipidus.

**Why the Correct Answer is Right**
Chlorpropamide acts as an insulin secretagogue by binding to and closing ATP-sensitive potassium channels in pancreatic beta cells, leading to depolarization and insulin release. Additionally, it has a non-insulin-mediated effect on the posterior pituitary gland, stimulating the release of ADH (also known as vasopressin), which helps regulate water reabsorption in the kidneys. This dual action makes chlorpropamide a treatment option for both diabetes mellitus and diabetes insipidus.

**Why Each Wrong Option is Incorrect**
**Option A is incorrect** because Glibenclamide (also known as glyburide) is another first-generation sulfonylurea, but it does not have the same effect on ADH release as chlorpropamide. **Option B is incorrect** because Glibenclamide primarily acts as an insulin secretagogue without the additional effect on ADH release. **Option C is incorrect** because Glicazide is a second-generation sulfonylurea that works similarly to glibenclamide, without the unique property of enhancing ADH release. **Option D is incorrect** because Glipizide is also a second-generation sulfonylurea with a similar mechanism of action to glibenclamide, lacking the effect on ADH release.

**Clinical Pearl / High-Yield Fact**
Chlorpropamide's unique property of enhancing ADH release can lead to hyponatremia in susceptible patients, making it essential to monitor electrolyte levels closely in patients taking this medication.

**✓ Correct Answer: A. Chlorpropamide**